Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cengent Therapeutics Inc.

Division of Long-E International Inc.

Latest From Cengent Therapeutics Inc.

Enzon and NPS: One Brings the Bread, the Other Brings Wine

The financial markets are having a tough time understanding the combination of biotech companies Enzon and NPS Pharmaceuticals, perhaps because it doesn't follow the typical rationale for intra-biotech mergers. That is, it doesn't join competitors working with similar technologies or disease states. Rather, the companies have little overlap, an attraction they argue will result in a balanced, somewhat synergistic product portfolio. Still, they face the challenge of convincing divergent investor groups--earnings-oriented shareholders of Enzon and growth-chasing investors in NPS--that the resulting new company wo'n't be a hodge-podge of diverse technologies.
BioPharmaceutical Strategy

Plexus Vaccine Inc.

Plexus Vaccine Inc. is a genomics-driven vaccine development company with a platform based on computational drug discovery and immunological informatics. In the near term, it is using its expertise in B-cell-based vaccines to design novel vaccines against potential biowarfare agents Yersinia pestis (plague) and anthrax, but the company believes that its platform is expandable to broad potential uses.
BioPharmaceutical Platform Technologies

ReceptorBase Inc.

Data mining start-up ReceptorBase Inc. has been validating its service model by prospecting GPCRs, a family of receptors known to hold more pharmaceutical riches than any other. Focusing on receptor protein function, the company applies empirical data from known small molecules to search out atomic binding sites. It then uses proprietary computational methods to predict compound designs that are mostly likely to hit the right target.

Computational Drug Discovery

Computational drug discovery companies promise to unite data from many of the disparate steps pharmaceutical companies go through these days, to enable more efficient lead identification, optimization, and testing.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Structural Bioinformatics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Long-E International Inc.
  • Senior Management
  • Edward T Maggio, PhD, Chmn. & CEO
    Ralph R Barry, VP, CFO
    David D Muth, Pres. & COO
    Robert G Ingersoll, Sr. Dir., Sales
    Kal Ramnarayan, PhD, VP, CSO
  • Contact Info
  • Cengent Therapeutics Inc.
    Phone: (619) 675-2400
    10929 Technology Pl.
    San Diego, CA 92127